Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : Introducing Undruggable, a New Serial Podcast from Amgen R&D Exploring how Multispecifics can Usher in the Next Wave of Drug Discovery

10/21/2021 | 10:54am EST

Beginning October 21, Amgen's R&D podcast returns with the new series, Undruggable. Produced in partnership with The Scientist, Undruggable explores the latest wave of innovation, featuring conversations about the new types of multispecific medicines that have the potential to radically alter our concept of how drugs can work and pave the way for new therapies.

While breakthrough discoveries have been made, 85% of disease targets are still considered undruggable, which represents an ongoing barrier to developing medicines for complex diseases like cancer and autoimmune conditions. Undruggable discusses some of the latest advancements enabling scientists to make progress against these challenging diseases.

"We are in an exciting time for drug discovery and development. Once thought to be an insurmountable task, scientists are successfully tackling the problem of undruggable disease targets," said Ray Deshaies, senior vice president of Global Research at Amgen. "I'm thrilled to share these conversations that delve deeper into the ways scientists are designing medicines that go beyond what conventional drugs can accomplish."

Joining Deshaies are leaders from Amgen and premier research institutions discussing topics ranging from the promise of induced proximity platforms to the way DNA encoded libraries help scientists screen billions of molecules to find compounds that interact with tricky targets.

The first episode launches today, and the series continues with a new episode every Thursday through November 18. You can findUndruggable here or by subscribing to The Scientist's series LabTalk on Apple Podcasts, Spotify, Stitcher, Google Podcasts, or wherever you like to listen.

October 21: The Next Wave of Drug Development
Ryan Potts, Ph.D., executive director, Research and head of Induced Proximity Platform at Amgen

October 28: The Biology of PROTACs
Craig Crews, Ph.D., professor of Molecular, Cellular and Developmental Biology, Yale

November 4: Discovery at the DNA Encoded Library
Alex Gouliaev, Ph.D., vice president, Amgen Research Copenhagen

November 11: The Emerging IPP Toolkit
Carolyn Bertozzi, Ph.D., professor of Chemistry, Stanford

November 18: Induced Proximity: Reason for Optimism in Treating Cancer and Beyond
David Reese, M.D., executive vice president, Research and Development, Amgen

In addition to the podcast series, Amgen and The Scientist will host three live webinars digging deeper into the science behind the latest technologies aimed at treating undruggable diseases. Register to listen here.

Undruggable is the second of two serial podcasts in partnership with The Scientist. In the first series, DNA Unlocked, host Ray Deshaies takes listeners on a journey Amgen scientists and others have been on for the past 20 years to reveal the promise in the explosion of genome sequencing data to better understand human biology and transform drug research and development, and cure diseases. You can listen to the series here.


Amgen Inc. published this content on 21 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2021 14:53:01 UTC.

ę Publicnow 2021
All news about AMGEN INC.
12/07CANDID CONVERSATIONS : Ability Bettered Through Leadership and Education (ABLE)
12/07Amgen Announces New Data Being Presented At ASH 2021
12/06Amgen Announces New Data Being Presented At ASH 2021
12/06Amgen on Pace for Largest Percent Increase Since November 2020 -- Data Talk
12/06Amgen Shares Rise After Goldman Sachs Begins Coverage at Buy
12/06Goldman Sachs Starts Amgen at Buy With $258 Price Target
12/06Amgen Announces 10% Increase in 2022 First Quarter Dividend
12/03AMGEN : Bradway Hails Amgen's Progress Against 'Undruggable' Disease Targets at Two Health..
12/03Amgen Raises Fiscal Q1 Dividend 10% to $1.94 a Share, Payable March 8 to Shareholders o..
12/03Amgen Announces 10% Increase In 2022 First Quarter Dividend
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 019 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 522 M - -
P/E ratio 2021 21,6x
Yield 2021 3,27%
Capitalization 120 B 120 B -
EV / Sales 2021 5,49x
EV / Sales 2022 5,19x
Nbr of Employees 24 300
Free-Float 99,8%
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 213,53 $
Average target price 239,73 $
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-7.13%120 274
JOHNSON & JOHNSON4.42%432 641
ROCHE HOLDING AG20.68%329 493
PFIZER, INC.39.64%288 501
NOVO NORDISK A/S73.12%256 630